INAB supply chain intelligence for IN8bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
IN8bio, Inc. (INAB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| EMORY-UNIVERSITY | EMORY-UNIVERSITY | 90% | The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. |
| UABRF | UABRF | 85% | In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued 3, |
| ADAPY | ADAPY | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from INAB graph: Reciprocal relationship from ADAPY graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement… |
| ALLO | Allogene Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given … |
| BMY | Bristol-Myers Squibb Company | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Give… |
| BMYMP | Bristol-Myers Squibb Co | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| CELG-RI | CELG-RI | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Gi… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| EDIT | Editas Medicine, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from INAB graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from INAB graph: Reciprocal relationship from EDIT g… |
| HCWB | HCW Biologics Inc. | 72% | Reciprocal relationship from HCWB graph: Reciprocal relationship from INAB graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from INAB graph: Reciprocal relationship from HCWB g… |
| HCWB | HCW Biologics Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| IPSC | Century Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| JANX | Janux Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| STTK | Shattuck Labs, Inc. | 72% | Reciprocal relationship from STTK graph: Reciprocal relationship from INAB graph: Reciprocal relationship from STTK graph: Reciprocal relationship from INAB graph: Reciprocal relationship from STTK g… |
| STTK | Shattuck Labs, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAPY | ADAPY | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Give… |
| ALLO | Allogene Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from INAB graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from INAB graph: Reciprocal relationship from ALLO g… |
| BMY | Bristol-Myers Squibb Company | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from INAB graph: Reciprocal relationship from BMY graph: Reciprocal relationship from INAB graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from INAB graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from INAB graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| CELG-RI | CELG-RI | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Gi… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| EDIT | Editas Medicine, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| HCWB | HCW Biologics Inc. | 72% | Reciprocal relationship from HCWB graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| HCWB | HCW Biologics Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| IPSC | Century Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from INAB graph: Reciprocal relationship from IPSC g… |
| JANX | Janux Therapeutics, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: Reciprocal relationship from INAB graph: Reciprocal relationship from JANX graph: Reciprocal relationship from INAB graph: Reciprocal relationship from JANX g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from INAB graph: Reciprocal relationship from REGN graph: Reciprocal relationship from INAB graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| STTK | Shattuck Labs, Inc. | 72% | Reciprocal relationship from STTK graph: Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given… |
| STTK | Shattuck Labs, Inc. | 72% | nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not yet established a commercial organization o… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | perience in these areas. In addition, there are complex regulatory, immigration, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, including… |
| EMERGING-GROWTH-COMPANY | EMERGING-GROWTH-COMPANY | 62% | Such increases may impact our labor costs and research and development costs, due to supply chain constraints, consequences associated with geopolitical tensions existing and any future tariffs enact… |
| NASDAQ-STOCK-MARKET-LLC | NASDAQ-STOCK-MARKET-LLC | 62% | perience in these areas. In addition, there are complex regulatory, immigration, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, including… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| INAB-DEBT-10262 | Warrants outstanding: 231396 | 90% | xbrl warrant detail from xbrl 2020-12-31. |
| INAB-DEBT | Debt stack $2.4M | 90% | Market cache reports total debt of $2.4M. |
| INAB-DEBT-10263 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| INAB-OWNER-ALYESKA-INVESTMENT-GROUP-L-P | Alyeska Investment Group, L.P. | 90% | 13F overlay lists Alyeska Investment Group, L.P. as top holder; 22 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HCWB | HCW Biologics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| STTK | Shattuck Labs, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CGEM | Cullinan Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IPSC | Century Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JANX | Janux Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ADAPY | Adaptimmune Therapeutics PLC | 100.00 | 1 | ['customer', 'supplier'] |
| EDIT | Editas Medicine, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| CUE | Cue Biopharma, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| ALLR | Allarity Therapeutics, Inc. | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 |